Interventional Glaucoma

A research team led by the Department of Ophthalmology, School of Clinical Medicine, LKS Faculty of Medicine of The University of Hong Kong, with collaborators from the Faculty of Medicine of The Chinese University of Hong Kong and local and international partners, have developed a new technology ROTA to unveil the optical texture and trajectories of the axonal fiber bundles on the retina.

Timing of type 2 diabetes or hypertension diagnosis may impact the risk of primary open-angle glaucoma.

According to researchers, findings could lead to new screening protocols to catch glaucoma early and preserve vision.

The investigators explained that elevated angle-closure-related intraocular pressure may aggregate the visual impairment in patients with retinitis pigmentosa.

The first cases in the United States using the company’s suprachoroidal technology were performed earlier this month, and long-term clinical outcomes will be presented at the annual meeting of the American Academy of Ophthalmology in Chicago, starting Sept. 30.

The research points to the importance of isolating offending organism.

Physicians may need to recognize issues and treat patients more holistically.

According to Sarah Van Tassel, MD, physicians may need to recognize issues and treat patients more holistically.

Although the standard of care remains the pharmaceutical option, surgeons would like to see other options for individualised treatment, including artificial intelligence and sustained-release technologies.

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

APOE4 gene associated with Alzheimer’s disease risk was found to protect mice from glaucoma. Research team also prevented retinal ganglion cell death by blocking the APOE signaling pathway, pointing to a potential treatment strategy for glaucoma.

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

According to the company, a study shows the non-implantable minimally invasive glaucoma surgery effectively reduces IOP and reduces need for IOP-lowering medications in patients diagnosed with open-angle glaucoma.

According to Johns Hopkins Medicine researchers, as little as $65 per year appears to influence practitioners, making them up to twice as likely to prescribe the companies’ brand name eyedrops for glaucoma instead of cheaper generic versions.

Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study. This measurement could potentially be used as a first-line indicator to monitor of glaucoma progression for the patient and the physician.

According to a new study from New York Eye and Ear Infirmary of Mount Sinai, a new, non-invasive ocular imaging method may be able to detect an early indicator of glaucoma in time to prevent disease progression and vision loss.

Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study.

The doctors will join the Cataract and Primary Eye Care, Glaucoma, and Retina Services.

Bausch + Lomb has made an equity investment in Sanoculis and has entered into an exclusive European distribution agreement for MIMS minimally invasive surgical procedure.

Mount Sinai study could lead to earlier and increased screening for this population to prevent blindness.

Janet B. Serle, MD, discusses the pros and cons of various treatment options.

A novel eye drop under development may provide neuroprotection to the retinal ganglion cells.

Researchers at the University of Strathclyde have developed an affordable device which takes 3D images and could shift the landscape of eye screening and treatment around the world.

The program — entitled “Pumping Adrenaline!” — brings viewers myriad challenging cases, intraoperative complications, and complex problems following cataract surgery.